Evolution of intravesical immunotherapy for bladder cancer: Mycobacterial cell wall preparation as a promising agent

Expert Opinion on Investigational Drugs

Volumn 17, Issue 7, 2008, Pages 1067-1073

  Morales, Alvaro ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Bladder cancer; Immunotherapy; Intravesical administration; Mycobacterial cell walls; Mycobacterium phlei

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL DNA; BCG VACCINE; CYTOTOXIC AGENT; IMMUNOMODULATING AGENT; LIVE VACCINE; MINERAL OIL; MITOMYCIN C; MYCOBACTERIAL CELL WALL COMPLEX; MYCOBACTERIAL CELL WALL EXTRACT; POLYSORBATE 80; SODIUM CHLORIDE; THIOMERSAL;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACTERIAL CELL WALL; BCG VACCINATION; BLADDER BIOPSY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CHILL; CLINICAL TRIAL; CYSTOSCOPY; DRUG EFFICACY; DRUG FEVER; DRUG INSTILLATION; DRUG SAFETY; DYSURIA; EMULSION; EPIDIDYMIS DISEASE; FATIGUE; FEVER; FLU LIKE SYNDROME; HEMATURIA; HUMAN; IMMUNOMODULATION; LIVER DISEASE; LUNG DISEASE; MALAISE; MICTURITION DISORDER; MYCOBACTERIUM PHLEI; NONHUMAN; PROSTATE DISEASE; RASH; RISK REDUCTION; SEPSIS; SIDE EFFECT; URINARY FREQUENCY; URINARY URGENCY; URINE CYTOLOGY; WEIGHT REDUCTION;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL WALL; EMULSIONS; HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM PHLEI; URINARY BLADDER NEOPLASMS;

EID: 48249113270     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.7.1067     Document Type: Article

References (33)

1. Pantuck AJ, Baniel J, Kirkali Z, et al. A novel resectoscope for transurethral resection of bladder tumors and the prostate. J Urol 2007;178:2331-6
2. O'Donnell MA, Practical applications of intravesical chemotherapy and immunotherapy in high risk patients with superficial bladder cancer. Urol Clin North Am 2005;32;121-31
3. Maffezzini M, Campodonico F, Canepa G, et al. Short schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, Gi-G2, low or intermediate risk, transitional cell carcinoma of the bladder. Eur Urol 2007;51:956-61
4. Morales A, Bruce A, Eidinger D. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-4
5. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000;163:1124-9
6. Morales A. Treatment of carcinoma in situ of the bladder with BCG. Cancer Immunol Immunother 1980;9:69-72
7. Glashan AW. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 1990;144:658-63
8. Stavropoulos NE, Hastazris K, Filiadis I, et al. Intravesical instillations of interferon gamma in the prophylaxis of high risk bladder cancer. Scand J Urol Nephrol 2002;36:218-22
9. Jurincic CD, Engelman U, Gasch J, Klippel K. Immunotherapy in bladder cancer with key-hole lympet hemocyanin: a randomized study. J Urol 1988;139:723-6
10. Kaasinen E, Wijkström H, Malmström PU, et al. Alternative mytomicin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 2003;43:637-45
11. Maymi JL, O'Donnell MA. Factors affecting response to BCG plus interferon in patients with urothelial carcinoma in situ (CIS). J Urol 2005;173:248
12. Lamm DL, van der Meijden APM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin in intravesical therapy of superficial bladder cancer. J Urol 1992;147:596-600
13. Morales Nickel JC, Wilson JWL. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 1992;147:1256-8
14. Martinez-Pineiro JA, Solsona E, Flores N, Isoma S. Improving the safety of BCG immunotherapy by dose reduction. Eur Urol 1995;27(Suppl):13-8
15. Klein WR, Ruitenberg EJ, Steerenberg PA, et al. Immunotherapy by intravesical injection of BCG cell walls or live BCG in bovine ocular squamous cell carcinoma: a preliminary report. J Natl Cancer Inst 1982;69:1099
16. Ribi EE, Granger DL. Milne KC. Tumor regression by endotoxins and mycobacterial fractions. J Natl Cancer Inst 1975;55:1253-8
17. Shimada S, Yano O, Inoue H. Antitumor activity of the DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors. J Natl Cancer Inst 1985;74:681-6
18. Di Paola RS, Lattime EC. Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy. J Urol 2007;178:1840-1
19. Sylvester RJ, van der Meijden APM, Wijes JA, Kurth K. Bacillus Calmette Guerin versus chemotherapy for intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urof 2005;174:86-92
20. Morales A, Manley P. Intralesional administration of microparticulate BCG components. J Urol 1985;133:122A
21. Morales A, Nickel JC, Downey J, et al. Immunotherapy of an experimental adenocarcinoma of the prostate. J Urol 1995;153:1706-10
22. Chin JL, Kadhim SA, Batislam E, et al. Mycobacterium cell wall: an alternative to intravesical BCG therapy in orthotopic murine bladder cancer. J Urol 1996;156:1189-93
23. Meyer TJ. Ribi EE, Azuma I, et al. Biologically active compounds from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma. J Natl Cancer Inst 1974;52:103-8
24. Gray GR, Ribi E, Granger D, et al. Immunotherapy of cancer: tumor suppression and regression by cell walls of Mycobacterium phlei attached to oil droplets. J Natl Cancer Inst 1975;55:727-30
25. Morales A, Chin J, Ramsey EW. Mycobacterial cell wall extract in the treatment of carcinoma in situ of the bladder. J Urol2001;166:1633-6
26. Lamm DL, Steg A, van der Meidjen, et al. Incidence and complications of treatment with Bacillues Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-605
27. Zlotta AR,van Vooren J-P, Denis O, et al. What are the immunologically active components of bacilli Calmette-Guerin in therapy of superficial bladder cancer? Int J Cancer 2000;87:844-52
28. Filion MC, Lepicier P, Morales A, Phillips N. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Br J Cancer 1999;79:229-35
29. Sasaki A, Kudoh S, Mori K, et al. Are BCG affects against urinary bladder carcinoma cell line T-24 correlated with apoptosis in vitro? Urol Int 1997;59:142-5
30. Bevers RFM, Kurth K-H, Schamhart DHJ. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 2004;91:607-12
31. Simons MP, Moore JM, Griffith TJ, Thomas S. Identification of mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-induced ligand from human neutrophils. Infect Immun 2007;75:1265-71
32. Filion MC, Filion B, Reader S, et al. Modulation of interleukin-12 by DNA lacking the CpG motif and present in a mycobacterial cell well complex. Cancer Immunol Immunother 2000;49;325-34
33. Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy. Urol Oncol 2008;26:137-40